AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

European officials are coming under increasing pressure to reverse restrictions on who can receive the AstraZeneca Covid vaccine.

Pressured European officials are trying to drum up support for the AstraZeneca Covid vaccine

BioNTech SE

Pfizer

France revises its stance and approves the AstraZeneca–Oxford vaccine for the over-65s.

Single dose of AstraZeneca or Pfizer COVID-19 vaccine cuts hospitalization risk by up to 80%, study shows

A recent study revealed that one dose of either Pfizer Inc (NYSE: PFE)/BioNtech SE (NASDAQ: BNTX) or Oxford-AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine is more than 80% effective in reducing infections and severe illness among those aged over 80, Reuters reports. Public Health England (PHE) found that the Pfizer jab offered between 57% and 61% protection against catching the disease after the first dose.

AstraZeneca, Pfizer/BioNtech Single Shot COVID-19 Jab 80% Effective At Preventing Hospitalizations In Elderly

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) from May 21, 2020 through November 20, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AstraZeneca PLC investors under the federal securities laws.

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AstraZeneca PLC– AZN

Moderna

The cash from the sale of its Moderna holding will help shore up AstraZeneca's finances as it continues to develop its drug pipeline.

AstraZeneca Sold Its Stake in Rival Vaccine Maker Moderna for Over $1 Billion

AstraZeneca plc (LON:AZN) has reportedly cashed in US$1.2bn after selling its 7.7% stake in COVID-19 vaccine maker Moderna, Inc. (NASDAQ:MRNA). The FTSE 100 pharma giant will use the proceeds to shore up its balance sheet as it is about to complete the US$39bn acquisition of US rare diseases specialist Alexion, its biggest yet, The Times reported.

AstraZeneca reportedly cashes in US$1.2bn after selling Moderna, Inc. stake

The sale comes after shares in COVID-19 vaccine maker Moderna soared fivefold in 2020.

AstraZeneca sold its stake in Moderna for more than $1 billion last year

AstraZeneca stock was subject to wild swings in 2020 as the company pushed forward in developing a coronavirus vaccine. Now that the firm has authorization in the U.K., is AZN stock a buy?

South Africa Variant Flummoxes AstraZeneca Vaccine; Is AZN Stock A Buy?

AstraZeneca Plc (NASDAQ: AZN) has announced a deal with Shanghai Junshi Biosciences Co Ltd to market Junshi's cancer drug. Under the agreement, AstraZeneca will be granted the right to market Junshi's anti-PD-1 cancer drug toripalimab for urothelial carcinoma across China and other cancer types in some areas.

AstraZeneca, Junshi Bio In Commercialization Pact For Toripalimab In China

British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has sold its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for more than $1 billion, the Times reported Sunday. What Happened: AstraZeneca disposed of its stake in Moderna following the U.S. biotechnology company's coronavirus vaccine breakthrough, according to the Times report.

AstraZeneca Divests Entire 7.7% Stake In Moderna For $1B: The Times

AstraZeneca Plc has sold its stake in Moderna Inc for more than $1 billion after the American biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Times reported.

Astrazeneca has sold its stake in Moderna for more than $1 billion: The Times

NEW YORK, Feb. 28, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff...

AZN BREAKING NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline - AZN

Amgen

AstraZeneca Plc (NASDAQ: AZN) and its partner Amgen Inc (NASDAQ: AMGN) have announced positive results from NAVIGATOR Phase 3 trial evaluating tezepelumab in severe asthma. Results were presented at the American Academy of Asthma Allergy & Immunology Annual Meeting.

AstraZeneca/Amgen's Tezepelumab Reduces Asthma Exacerbations, Phase 3 Trial Shows

LOS ANGELES, Feb. 26, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities...

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

AZN Breaking Alert: Rosen, A Leading Law Firm, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline - AZN

Bit Digital, Inc

CleanSpark

9F Inc - ADR

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bit Digital, Inc. (NASDAQ: BTBT), CleanSpark, Inc. (NASDAQ: CLSK), 9F, Inc. (NASDAQ: JFU), and AstraZeneca PLC (NASDAQ: AZN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bit Digital, CleanSpark, 9F, Inc., and AstraZeneca and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AstraZeneca securities between May 21, 2020 and November 20, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/azn. Th

AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Anglo-Swedish drug company hopes to deliver 180 million doses to the 27-member bloc by June.

AstraZeneca is aiming to meet EU second-quarter COVID-19 vaccine targets, despite reports

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEX

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN

Shares of AstraZeneca were up 0.1% in after-hours trading on Tuesday after a company executive testified before Congress that the drug maker expects to deliver 50 million of its experimental COVID-19 vaccine in the U.S. in April if it's authorized before then. That would be enough to vaccinate 25 million people.

AstraZeneca exec tells Congress it could have 50 million doses of its COVID-19 vaccine ready in April

AstraZeneca is a company going through a transformation.

AstraZeneca Growth Is Back And The Progressive Dividend Will Follow

AstraZeneca plc (NASDAQ: AZN) announced Monday a setback related to its key immuno-oncology therapy Imfinzi. What Happened: The U.K. drugmaker said it is voluntarily withdrawing Imfinzi from the U.S. market as a treatment option for previously treated adult patients with locally advanced or metastatic bladder cancer.

Why AstraZeneca Is Voluntarily Withdrawing Imfinzi In US For Advanced Bladder Cancer Indication

Shares of AstraZeneca were down 0.1% in trading on Monday after the drugmaker said it voluntarily withdrew an indication granted by the Food and Drug Administration that allows the use of Imfinzi as a treatment for certain types of bladder cancer. The FDA initally granted the company an accelerated approval in 2017 for this drug with this indication; however, the approval required additional studies, and AstraZeneca found that the drug did not meet the primary endpoints in a study conducted in 2020.

AstraZeneca to withdraw drug used to treat bladder cancer

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

News for AstraZeneca Stock (AZN)